Pioglitazone

Revision as of 09:20, 11 November 2010 by David Canner (Talk | contribs)

Marketed By: Takeda Pharmaceuticals
Major Indication: Hypoglycemia & Type 2 Diabetes
Drug Class: PPAR-γ Activator - Thiazolidinedione (Glitazones)
Date of FDA Approval (Patent Expiration): 1999 (2011)
2009 Sales: $2.4 Billion ^[1]
Why You Should Care: It is the best selling drug to treat Diabetes and is the 10th best selling drug in the United States.
The following is a list of Pharmacokinetic Parameters. See: Pharmaceutical Drugs for more information